Long noncoding RNA SGO1-AS1 inactivates TGFβ signaling by facilitating TGFB1/2 mRNA decay and inhibits gastric carcinoma metastasis

Donglan Huang, Ke Zhang, Wenying Zheng, Ruixin Zhang, Jiale Chen, Nan Du, Yuanyuan Xia, Yan Long, Yixue Gu, Jianhua Xu, Min DengJournal of Experimental & Clinical Cancer Research 2021 · DOI

TL;DR

This study identifies a long noncoding RNA (lncRNA), SGO1-AS1, that acts as a tumor suppressor in gastric cancer by inhibiting metastasis. SGO1-AS1 achieves this by destabilizing TGFB1/2 mRNA, thereby dampening the pro-metastatic TGF-beta signaling pathway, and is itself regulated by a feedback loop involving TGF-beta and the transcription factor ZEB1.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant global health challenge, with metastasis being a primary driver of mortality. While the role of various molecular players in GC progression is being uncovered, the intricate regulatory mechanisms governing metastasis, particularly those involving non-coding RNAs, are not fully understood. This paper aims to identify novel lncRNAs involved in GC metastasis and elucidate their underlying molecular mechanisms, seeking to uncover new therapeutic targets.

Methods

The researchers employed a multi-pronged approach:

  • Microarray Analysis: To identify differentially expressed lncRNAs between GC tissues and adjacent normal tissues.
  • Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR): To validate lncRNA expression levels and quantify the expression of key genes (SGO1-AS1, TGFB1/2, ZEB1, PTBP1).
  • In Situ Hybridization (ISH): To visualize the spatial expression of SGO1-AS1 in GC tissues.
  • Gain-of-Function and Loss-of-Function Studies: Using lentiviral vectors to overexpress or knockdown SGO1-AS1 in GC cell lines to assess its functional impact on invasion, migration, and metastasis.
  • RNA Pull-down and RNA Immunoprecipitation (RIP) Assays: To identify and validate protein-RNA interactions, specifically focusing on SGO1-AS1 and its binding partners.
  • Western Blotting: To assess protein expression levels of key signaling molecules (e.g., TGF-beta, SMADs, EMT markers, PTBP1, ZEB1).
  • Luciferase Reporter Assays: To investigate the regulatory effects of ZEB1 on SGO1-AS1 promoter activity and the impact of TGF-beta signaling on SBE4 transcriptional activity.
  • Cell-based Assays: Including Transwell assays (invasion), wound-healing assays (migration), soft agar colony formation assays (anchorage-independent growth), and sphere culture assays (stemness).
  • Animal Models: Xenograft models in nude mice were used to evaluate the in vivo effects of SGO1-AS1 on tumor metastasis and growth.
  • Bioinformatics Analysis: Including GSEA and promoter analysis to identify potential regulatory pathways and transcription factor binding sites.

Datasets

  • Microarray Data: Deposited in the Gene Expression Omnibus (GEO) database under accession numbers GSE157289, GSE157582, and GSE157941.
  • TCGA Stomach Adenocarcinoma RNA-seq Dataset: Used for Gene Set Enrichment Analysis (GSEA) to correlate SGO1-AS1 expression with TGF-beta target genes.
  • Clinical Samples: Paired gastric cancer (GC) and adjacent normal mucosal tissues from three cohorts (n=5, n=92, n=95+80) were used for microarray, qRT-PCR, and ISH analyses, respectively.

Key Insights and Ideas

  • SGO1-AS1 as a Metastasis Suppressor: The study establishes SGO1-AS1 as a novel lncRNA that actively inhibits GC cell invasion and metastasis, both in vitro and in vivo. This is a significant finding as it identifies a new player in the complex process of cancer spread.
  • Mechanism of TGF-beta Regulation: A key insight is how SGO1-AS1 exerts its suppressive effect: by binding to the RNA-binding protein PTBP1. This interaction competitively displaces TGFB1/2 mRNA from PTBP1, leading to increased mRNA decay and reduced TGF-beta protein production. This reveals a novel post-transcriptional regulatory mechanism for TGF-beta.
  • Double-Negative Feedback Loop: The study uncovers a sophisticated regulatory loop where TGF-beta signaling, induced by factors like ZEB1, downregulates SGO1-AS1 transcription. Conversely, SGO1-AS1 suppresses TGF-beta signaling. This reciprocal inhibition creates a stable feedback mechanism that influences metastasis.
  • ZEB1 as a Key Mediator: ZEB1 emerges as a crucial transcription factor that links TGF-beta signaling to SGO1-AS1 downregulation. This finding highlights the interconnectedness of key pathways in cancer progression.
  • Clinical Relevance: The downregulation of SGO1-AS1 in GC tissues, and its correlation with advanced clinical stage, lymph node metastasis, and poor patient prognosis, underscores its clinical significance and potential as a biomarker.

Key Results

  • SGO1-AS1 was significantly downregulated in GC tissues compared to normal tissues, with its low expression correlating with advanced stage and metastasis.
  • Overexpression of SGO1-AS1 inhibited GC cell invasion, migration, and metastasis in vitro and in vivo. Conversely, knockdown of SGO1-AS1 promoted these processes.
  • SGO1-AS1 directly interacts with PTBP1, leading to destabilization and reduced expression of TGFB1/2 mRNA and protein.
  • TGF-beta signaling, through the induction of ZEB1, transcriptionally represses SGO1-AS1 expression.
  • SGO1-AS1 knockdown led to increased EMT markers (Vimentin, N-cadherin) and EMT-inducing transcription factors (ZEB1, SNAI), which were reversed by PTBP1 knockout or TGF-beta inhibition.
  • SGO1-AS1 overexpression reduced TGF-beta secretion and autocrine signaling, impacting cell invasion and migration.
  • High expression of TGFB1/2 and ZEB1 was observed in GC tissues and correlated with metastasis, while being inversely correlated with SGO1-AS1 expression.

Limitations and Future Work

  • PTBP1 Binding Site Specificity: While the study identified the RRM2 domain of PTBP1 as crucial for binding SGO1-AS1, further detailed structural studies could elucidate the precise molecular interactions.
  • Other SGO1-AS1 Interacting Proteins: The study identified G3BP2 as another potential SGO1-AS1 interacting protein, but its role in GC metastasis was not explored. Future work could investigate its contribution.
  • ZEB1 Interference: The authors suggest that interference with ZEB1 might be a therapeutic avenue, but this requires further confirmation through future studies.
  • Therapeutic Potential: The findings strongly suggest SGO1-AS1 as a potential therapeutic target. Future research could focus on developing strategies to restore SGO1-AS1 levels or inhibit the TGF-beta/ZEB1 axis in GC.

Summary updated

Abstract

SGO1-AS1 functions as an endogenous inhibitor of the TGFβ pathway and suppresses gastric carcinoma metastasis, indicating a novel potential target for GC treatment.
BibTeX
@article{huang2021long,
  author = {Donglan Huang and Ke Zhang and Wenying Zheng and Ruixin Zhang and Jiale Chen and Nan Du and Yuanyuan Xia and Yan Long and Yixue Gu and Jianhua Xu and Min Deng},
  title = {{Long noncoding RNA SGO1-AS1 inactivates TGFβ signaling by facilitating TGFB1/2 mRNA decay and inhibits gastric carcinoma metastasis}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2021},
  doi = {10.1186/s13046-021-02140-0},
}
Figure